** Shares of drugmaker Karyopharm Therapeutics KPTI.O rise 16% to $7.78 premarket

** Co says its selinexor-plus-ruxolitinib combo met one of two main goals in a late‑stage trial in myelofibrosis, a rare blood cancer that causes bone marrow scarring and an enlarged spleen

** Trial met the spleen size reduction goal but did not show a clear difference on symptom improvement versus ruxolitinib alone, co says

** Co also flagged a possible survival benefit signal and said it plans to meet the FDA to discuss next steps

** Shares fell ~27% in 2025